{"id":"placebo-golimumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tuberculosis reactivation"}]},"_chembl":{"chemblId":"CHEMBL1201833","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Golimumab is a fully human monoclonal antibody that specifically targets TNF-α, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By blocking TNF-α, it suppresses the inflammatory cascade and reduces immune-mediated tissue damage. This mechanism is effective in conditions where TNF-α plays a central pathogenic role, such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.","oneSentence":"Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:34.297Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT05242484","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-19","conditions":"Colitis, Ulcerative","enrollment":577},{"nctId":"NCT05071664","phase":"PHASE2","title":"A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-25","conditions":"Arthritis, Psoriatic","enrollment":91},{"nctId":"NCT05242471","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-22","conditions":"Crohn's Disease","enrollment":703},{"nctId":"NCT02186873","phase":"PHASE3","title":"A Study of Golimumab in Participants With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-03","conditions":"Ankylosing Spondylitis","enrollment":208},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT04997733","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-22","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT02846545","phase":"PHASE2","title":"A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-26","conditions":"Diabetes Mellitus, Type 1","enrollment":84},{"nctId":"NCT03298542","phase":"PHASE1","title":"A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-16","conditions":"Pre-Symptomatic Type 1 Diabetes","enrollment":8},{"nctId":"NCT03662542","phase":"PHASE2","title":"A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-20","conditions":"Colitis, Ulcerative","enrollment":214},{"nctId":"NCT03253796","phase":"PHASE4","title":"Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-07","conditions":"Spondyloarthritis","enrollment":323},{"nctId":"NCT04729296","phase":"PHASE2","title":"Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 1","enrollment":""},{"nctId":"NCT02065713","phase":"PHASE3","title":"Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"Instituto de Medicina Molecular João Lobo Antunes","startDate":"2014-08","conditions":"Psoriatic Arthritis","enrollment":44},{"nctId":"NCT04531423","phase":"NA","title":"PKC as Serum Biomarkers for Depression","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-10-01","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT01426815","phase":"PHASE3","title":"Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2012-03-13","conditions":"Peripheral Spondylarthritis","enrollment":60},{"nctId":"NCT01453725","phase":"PHASE3","title":"Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-13","conditions":"Spondylitis, Ankylosing","enrollment":198},{"nctId":"NCT01871649","phase":"PHASE3","title":"Initial Treatment With Golimumab in Early PsA","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-08","conditions":"Psoriatic Arthritis","enrollment":51},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT02181673","phase":"PHASE3","title":"A Study of Golimumab in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-08","conditions":"Arthritis, Psoriatic","enrollment":480},{"nctId":"NCT01217814","phase":"PHASE2","title":"Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT01863771","phase":"PHASE3","title":"A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-03-15","conditions":"Colitis, Ulcerative","enrollment":144},{"nctId":"NCT01715896","phase":"PHASE2","title":"A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":215},{"nctId":"NCT00488631","phase":"PHASE3","title":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2007-09","conditions":"Colitis, Ulcerative","enrollment":1228},{"nctId":"NCT01230827","phase":"PHASE3","title":"A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-12","conditions":"Juvenile Idiopathic Arthritis","enrollment":173},{"nctId":"NCT00771251","phase":"PHASE3","title":"A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-05","conditions":"Rheumatoid Arthritis","enrollment":311},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT00675649","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma","status":"WITHDRAWN","sponsor":"Centocor, Inc.","startDate":"2008-05","conditions":"Asthma","enrollment":""},{"nctId":"NCT01212653","phase":"PHASE4","title":"Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS)","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2010-10","conditions":"Ankylosing Spondylitis(AS)","enrollment":50},{"nctId":"NCT00264537","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Rheumatoid Arthritis","enrollment":637},{"nctId":"NCT00361335","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":643},{"nctId":"NCT00955279","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-11","conditions":"Sarcoidosis","enrollment":173},{"nctId":"NCT00264550","phase":"PHASE3","title":"An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Rheumatoid Arthritis","enrollment":444},{"nctId":"NCT00299546","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2006-02","conditions":"Arthritis, Rheumatoid","enrollment":461},{"nctId":"NCT00487539","phase":"PHASE2, PHASE3","title":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2007-08","conditions":"Colitis, Ulcerative","enrollment":1065},{"nctId":"NCT00973479","phase":"PHASE3","title":"An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":592},{"nctId":"NCT01248780","phase":"PHASE3","title":"Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":264},{"nctId":"NCT01258777","phase":"PHASE1","title":"A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2010-10","conditions":"Healthy Volunteers","enrollment":49},{"nctId":"NCT00265083","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Spondylitis, Ankylosing","enrollment":356},{"nctId":"NCT00265096","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Arthritis, Psoriatic","enrollment":407},{"nctId":"NCT00488774","phase":"PHASE2, PHASE3","title":"An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2007-08","conditions":"Colitis, Ulcerative","enrollment":291},{"nctId":"NCT00727987","phase":"PHASE3","title":"A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-05","conditions":"Rheumatoid Arthritis","enrollment":269},{"nctId":"NCT01248793","phase":"PHASE3","title":"Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2010-10","conditions":"Ankylosing Spondylitis","enrollment":213},{"nctId":"NCT00207714","phase":"PHASE2","title":"An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2003-11","conditions":"Rheumatoid Arthritis","enrollment":172},{"nctId":"NCT00207740","phase":"PHASE2","title":"A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2004-08","conditions":"Asthma","enrollment":309}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":279,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo; golimumab","genericName":"Placebo; golimumab","companyName":"Centocor, Inc.","companyId":"centocor-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}